Thursday, September 30, 2004

Financing Drug Research: What Are the Issues?
Report from the Center for Economic and Policy Research - "Rising drug prices are placing an ever larger burden on family budgets and the economy. The Center for Medicare and Medicaid Services estimates 2004 expenditures at $207 billion (more than $700 per person), and projects that annual spending will grow to more than $500 billion by 2013 (more than $1,600 per person). The immediate cause of high drug prices is government granted patent monopolies, which allow drug companies to charge prices that are often 400 percent, or more, above competitive market prices. Patent monopolies are one possible mechanism for financing prescription drug research. Rapidly increasing drug costs, and the economic distortions they imply, have led researchers to consider alternative mechanisms for financing drug research. This paper outlines some of the key issues in evaluating patents and other mechanisms for financing prescription drug research. It then assesses how four proposed alternatives to the patent system perform by these criteria."  
  

Two Schizophrenia Drugs Tied to Small Diabetes Risk
Reuters Health story at Yahoo - "Two drugs commonly prescribed for schizophrenia - clozapine and olanzapine -- may carry a small risk of an increased risk of diabetes, new research shows. The study of nearly 57,000 schizophrenia patients in the Veterans Affairs (VA) health system found that just over 7 percent developed diabetes over 1 to 2 years of follow-up. The risk of diabetes was higher among those who were on the antipsychotic drugs clozapine or olanzapine for at least 3 months during the study period. "  
  

FDA to Study Adult Antidepressant Effects
AP story at Yahoo - "The Food and Drug Administration will examine clinical trial data for thousands of depressed adults to see if they, like children, suffered increased suicidal thoughts and behaviors while taking antidepressants. Dr. Janet Woodcock, acting FDA (news - web sites) deputy commissioner, could not say how long the exhaustive analysis would take or how much it would cost. 'It's a huge undertaking,' Woodcock said Tuesday. Columbia University's analysis of pediatric clinical trial data examined just one-tenth of the information contained in adult databases. "